MédiMabs – CCAB series launch

MédiMabs is pleased to announce you that we have set an official agreement with the CCAB for the commercialization of their research reagents under the brand MédiMabs – CCAB series. We are starting with 19 new antibodies against various cell surface targets + an antibody panel against 6 different FGFR isoforms. All of these high quality antibodies were developed by CCAB on their phage display platform. You can read the full press release on CCAB website.

Written by
MédiMabs’ Team